Objectives: Utilization of dried blood spot (DBS) assay provides an alternative approach to conventional assays in blood or serum, particularly for neonates, older populations, and large-scale population-based studies. This study aimed to standardize the DBS-based bioassay for the estimation of glycated hemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), creatinine, and high-density lipoprotein-cholesterol (HDL-C), and to validate the levels of these analytes between venous and DBS. Materials and Methods: Blood samples were collected on filter paper, dried at room temperature, and eluted. HbA1c, hs-CRP, creatinine, and HDL-C levels were estimated in DBS and serum/plasma (whole blood in the case of HbA1c). Statistical analysis: DBS-to-serum equivalency was evaluated by linear regression analysis and Bland–Altman plot analysis to assess the agreement and bias between both assays. Results: The DBS assay was linear, sensitive, accurate, and precise with acceptable recovery and matrix effects for HbA1c, hs-CRP, creatinine, and HDL-C. Within- and between-batch precision was within an acceptable limit (<10% for all analytes). A strong correlation and agreement in Bland–Altman analysis were revealed between liquid and DBS measures for HbA1c (r 2 = 0.955), hs-CRP (r 2 = 0.973), and creatinine (r 2 = 0.953). However, a weak association was observed for HDL-C levels (r 2 = 0.572) between DBS and liquid bioassay. Conclusions: We conclude that the HbA1c, hs-CRP, creatinine, and HDL-C can be measured from DBS samples and are readily transferable to a liquid phase for analysis, offering a convenient alternative for monitoring cardiovascular disease risk factors.
Tarik et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: